An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures

Medtronic Spine LLC1 site in 1 country300 target enrollmentFebruary 2003

ConditionsOsteopenia Osteoporosis Multiple Myeloma Bone Neoplasms

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Osteopenia
Sponsor: Medtronic Spine LLC
Enrollment: 300
Locations: 1
Primary Endpoint: The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral compression fractures (VCFs).
Status: Completed
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral body compression fractures.

Registry

clinicaltrials.gov

Start Date

February 2003

End Date

December 2007

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Medtronic Spine LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Minimum of one painful, acute (edema present on MRI obtained within a two weeks period prior to enrolment) thoracic or lumbar (T5-L5) vertebral body compression fracture, due to osteopenia arising from primary or secondary osteoporosis, multiple myeloma, or osteolytic metastatic tumors and maximum of three painful fractures requiring treatment. (NOTE: a T2-weighted MRI should be done unless it is not available);
•Minimum of one acute fracture to be treated that has height loss \> 15% of predicted height (average height of two adjacent "normal" vertebrae) when measured at the middle of the vertebral endplate. (NOTE: If the adjacent vertebrae are not normal, the predicted height will be based on the height listed for the fractured vertebra in the table taken from Black et al.)
•Pre-treatment VAS score \> 4 on a scale of 10 where 0 is no pain, 5 is moderate pain and 10 is pain "as bad as you can imagine";
•Patient 21 years of age or older;
•The investigator and surgeon/radiologist agree before randomization that the fracture(s) can technically be reduced using an inflatable bone tamp (IBT); and
•A signed Informed Consent is obtained from the patient.

Exclusion Criteria

•Previous vertebroplasty;
•Vertebral body fracture morphology prevents use of devices (such as endplate below pedicles);
•Pedicle fractures;
•Acute fracture(s) to be treated symptomatic \> 3 months at enrollment;
•Pre-existing (not the result of the index fracture) neurological deficit or radicular pain that is not well defined or unstable;
•Spinal cord compression or canal compromise requiring decompression;
•Disabling back pain secondary to causes other than acute fracture;
•Vertebral fracture due to primary or osteoblastic tumors;
•Patient is currently on anticoagulation therapy that can not be interrupted;
•Pre-existing conditions contrary to the kyphoplasty procedure:

Outcomes

Primary Outcomes

The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral compression fractures (VCFs).

Safety will be compared between the study groups throughout the study with focus on clinically meaningful events and subsequent VCFs including the "treated" vertebrae.

The primary study endpoint is the change in quality of life as measured by the Physical Component Summary (PCS) scale of the 36-Item Short Form (SF-36) as measured at the one-month follow-up visit.

Secondary Outcomes

Maintenance of vertebral body height will be assessed from lateral spine x-rays obtained in Kyphoplasty treated subjects only at baseline and at 3, 12, and 24 month visits.
function as measured by objective functionality tests-reaching, "get up and go" and by the subjective Roland Morris disability questionnaire at 1, 3, 6, 12 and 24 months
outcome (nursing home, back to status prior to fracture) at 1, 3, 6, 12, 24 months
the cost-effectiveness of kyphoplasty expressed in incremental cost/quality adjusted life year gained at different time points (1 year and 2 years)
Each endpoint will be compared between the 2 groups and for its evolution over time.
procedural safety (peri-operative clinical events)
changes in spinal deformity as measured radiographically at baseline, 3, 12 and 24 months.
patient satisfaction at 1, 3, 6, 12, 24 months
economic aspects (including hospital days, disabilities, etc.) at 1, 3, 6, 12, 24 months
rate of incident fractures at 3, 12 and 24 months (frequency, timing and location)
The secondary study endpoints are: EuroQol self-report (EQ-5D) questionnaire and SF-36 scores at 1, 3, 6, 12 and 24 months
pain using a 10-point visual analogue scale (VAS) at 5-10 days (post enrollment for the control group and post kyphoplasty for the kyphoplasty group)